Toggle Main Menu Toggle Search

Open Access padlockePrints

Considerations for the cure assumption in a NICE Single Technology Appraisal of nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer: Evidence Assessment Group perspective

Lookup NU author(s): Giovany Orozco LealORCiD, Eugenie Johnson, Dr Sedighe Hosseinijebeli, Tomos Robinson, Tara HomerORCiD, Claire EastaughORCiD, Dr Louise TannerORCiD, Dr Nick MeaderORCiD, Dr Ryan KennyORCiD, Sheila WallaceORCiD, Stephen RiceORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Publication metadata

Author(s): Orozco Leal G, Johnson EE, Hosseinijebeli S, Robinson T, Homer T, Eastaugh C, Richmond C, Tanner L, Meader N, Kenny R, Wallace SA, Rice S

Publication type: Article

Publication status: Published

Journal: PharmacoEconomics

Year: 2024

Volume: 42

Pages: 133-136

Print publication date: 01/02/2024

Online publication date: 20/11/2023

Acceptance date: 09/10/2023

Date deposited: 11/12/2023

ISSN (print): 1170-7690

ISSN (electronic): 1179-2027

Publisher: Springer

URL: https://doi.org/10.1007/s40273-023-01328-w

DOI: 10.1007/s40273-023-01328-w

ePrints DOI: 10.57711/k6kc-8x77


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
NIHR135664
NIHR

Share